KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Liabilities and Shareholders Equity (2016 - 2025)

Inovio Pharmaceuticals' Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $68.2 million for Q2 2025.

  • For Q2 2025, Liabilities and Shareholders Equity fell 49.0% year-over-year to $68.2 million; the TTM value through Sep 2025 reached $268.7 million, down 34.75%, while the annual FY2024 figure was $113.2 million, 33.78% down from the prior year.
  • Liabilities and Shareholders Equity for Q2 2025 was $68.2 million at Inovio Pharmaceuticals, down from $87.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $654.9 million in Q1 2021 and bottomed at $68.2 million in Q2 2025.
  • The 5-year median for Liabilities and Shareholders Equity is $266.6 million (2023), against an average of $311.6 million.
  • The largest annual shift saw Liabilities and Shareholders Equity surged 93.22% in 2021 before it plummeted 50.95% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $495.9 million in 2021, then dropped by 29.72% to $348.5 million in 2022, then tumbled by 50.95% to $171.0 million in 2023, then tumbled by 33.78% to $113.2 million in 2024, then tumbled by 39.72% to $68.2 million in 2025.
  • Per Business Quant, the three most recent readings for INO's Liabilities and Shareholders Equity are $68.2 million (Q2 2025), $87.3 million (Q1 2025), and $113.2 million (Q4 2024).